David Sharp Joins Catalyst OrthoScience As VP of Global Marketing

David Sharp has joined Catalyst OrthoScience as Vice President of Global Marketing effective immediately.

“We are excited to have an executive with David’s experience join our team at Catalyst OrthoScience,” said Catalyst OrthoScience CEO and President Carl O’Connell. “As we continue to grow and establish our presence as an emerging global leader in shoulder pathology solutions, David’s leadership and experience will help make that vision a reality.”

“I am excited to join the Catalyst team and contribute to the company’s goals that focus on sustainable growth and delivering real solutions to clinical unmet needs for shoulder surgeons and their patients around the world,” Sharp said. “I will be focused on growing a best-in-class marketing team and brand as we continue to build our core foundations in sales, marketing, R&D, and MedEd.”

David Sharp brings more than 27 years of marketing, strategy, business development, communications and branding experience in the medical device industry, including roles with Sofamor Danek, Smith & Nephew, Medtronic Spinal & Biologics, Baxter International and most recently, MicroPort Orthopedics.

David Sharp received a Bachelor of Science in Business Administration from the University of Memphis and a Master’s in International Business from Christian Brothers University.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”